TITLE

Obesity Drug In the Wings

PUB. DATE
March 2005
SOURCE
Nutrition Business Journal;Mar2005, Vol. 10 Issue 3, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on French company Sanofi-Aventis' preparation for the launch of a weight loss drug called rimonabant, brand name Acomplia, in 2006. Drug's targeting of the endocannabinoid system in the brain, believed to play a role in regulating appetite; Estimated sales of the drug in the U.S. if it makes it to the market.
ACCESSION #
16846195

 

Related Articles

  • Advertisers get away with incredible weight-loss claims; how not to succumb.  // Environmental Nutrition;Jan1997, Vol. 20 Issue 1, p3 

    Presents advice on how not to succumb to unscrupulous weight-loss advertising in the United States. Includes use of common sense; Not trusting advertisements which offer immediate and guaranteed results; Power of the US Federal Trade Commission to stop fraudulent advertisements.

  • VLCDs may phase out.  // Obesity & Health;Jul/Aug93, Vol. 7 Issue 4, p67 

    Reports on very low calorie diet (VLCD) industry as declining. Drop of five percent in 1993; Public perception of its value; Willingness of medical insurance companies to pay; Diet Business Bulletin 1993, 2:1 as source.

  • Diet industry pounds at post-holiday plans. Fitzgerald, Kate; Liesse, Julie // Advertising Age;1/10/1994, Vol. 65 Issue 2, p8 

    Reports on the weight loss industry in the United States. Introduction of diet programs and products to cash in on consumer anxiety about post-holiday flab; Federal Trade Commission's charges of deceptive advertising against five weight loss centers; Appearance of television news anchorwoman...

  • Weight Watchers settles.  // Healthy Weight Journal;Mar/Apr98, Vol. 12 Issue 2, p19 

    Provides updates pertaining to the weight loss preparations industry in the United States as of March 1998. Settlements on the Federal Trade Commission's 1993 complaint against the major weight loss industries; Agreement with Weight Watchers International on the types of evidence needed for...

  • Leaner times for Rx diet drug makers could fatten OTC sales. Eder, Rob // Drug Store News;9/22/97, Vol. 19 Issue 15, pCP35 

    Discusses the future of the prescription diet/weight loss drug market. Concerns on the negative publicity surrounding prescription obesity drugs; Growth of the natural care products in the sector.

  • It's a fraud.  // Joe Weider's Muscle & Fitness;Jun94, Vol. 55 Issue 6, p41 

    Reports on the potential lies propagated by the manufacturers of weight-loss products and schemes. Warnings issued to consumers by the Food and Drug Administration.

  • Weight loss drugs get a boost.  // Medical Marketing & Media;Aug99, Vol. 34 Issue 8, p24 

    Reports on the effectiveness of anti-obesity drugs such as Xenical and Meridia. Shares of the drugs in the American anti-obesity market; Mechanisms of action; Results of clinical studies on the drugs.

  • THE VERDICT: It pains me to say it, but I'm an inch thinner. Adam Lee // Mail on Sunday;12/ 8/2013, p29 

    EFFORTLESSLY lose your beer gut? In days? Lead me to it!

  • Dieters ready for more ready-to-eat/drink formulas. Eder, Rob // Drug Store News;2/1/99, Vol. 21 Issue 2, p23 

    Provides information on the growth of over-the-counter diet/weight loss products at retail outlets of drug chains in the United States. Strength of the products in the market; How consumers view the diet/weight loss products; Top brands in diet/weight loss liquids and powders.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics